×
S&P 500   3,762.98 (-1.63%)
DOW   30,511.07 (-1.89%)
QQQ   279.49 (-0.94%)
AAPL   138.40 (-0.38%)
MSFT   256.31 (-1.26%)
META   161.58 (+0.97%)
GOOGL   2,175.65 (+0.04%)
AMZN   110.22 (+0.60%)
TSLA   663.10 (-2.74%)
NVDA   145.03 (-0.14%)
NIO   21.21 (-0.70%)
BABA   114.46 (-1.33%)
AMD   73.28 (-0.53%)
MU   54.43 (+1.45%)
CGC   2.66 (-5.34%)
T   20.83 (-2.25%)
GE   61.00 (-4.00%)
F   10.84 (-4.24%)
DIS   94.38 (-1.83%)
AMC   12.77 (-5.62%)
PFE   50.64 (-3.19%)
PYPL   71.76 (+0.50%)
NFLX   178.70 (-0.69%)
S&P 500   3,762.98 (-1.63%)
DOW   30,511.07 (-1.89%)
QQQ   279.49 (-0.94%)
AAPL   138.40 (-0.38%)
MSFT   256.31 (-1.26%)
META   161.58 (+0.97%)
GOOGL   2,175.65 (+0.04%)
AMZN   110.22 (+0.60%)
TSLA   663.10 (-2.74%)
NVDA   145.03 (-0.14%)
NIO   21.21 (-0.70%)
BABA   114.46 (-1.33%)
AMD   73.28 (-0.53%)
MU   54.43 (+1.45%)
CGC   2.66 (-5.34%)
T   20.83 (-2.25%)
GE   61.00 (-4.00%)
F   10.84 (-4.24%)
DIS   94.38 (-1.83%)
AMC   12.77 (-5.62%)
PFE   50.64 (-3.19%)
PYPL   71.76 (+0.50%)
NFLX   178.70 (-0.69%)
S&P 500   3,762.98 (-1.63%)
DOW   30,511.07 (-1.89%)
QQQ   279.49 (-0.94%)
AAPL   138.40 (-0.38%)
MSFT   256.31 (-1.26%)
META   161.58 (+0.97%)
GOOGL   2,175.65 (+0.04%)
AMZN   110.22 (+0.60%)
TSLA   663.10 (-2.74%)
NVDA   145.03 (-0.14%)
NIO   21.21 (-0.70%)
BABA   114.46 (-1.33%)
AMD   73.28 (-0.53%)
MU   54.43 (+1.45%)
CGC   2.66 (-5.34%)
T   20.83 (-2.25%)
GE   61.00 (-4.00%)
F   10.84 (-4.24%)
DIS   94.38 (-1.83%)
AMC   12.77 (-5.62%)
PFE   50.64 (-3.19%)
PYPL   71.76 (+0.50%)
NFLX   178.70 (-0.69%)
S&P 500   3,762.98 (-1.63%)
DOW   30,511.07 (-1.89%)
QQQ   279.49 (-0.94%)
AAPL   138.40 (-0.38%)
MSFT   256.31 (-1.26%)
META   161.58 (+0.97%)
GOOGL   2,175.65 (+0.04%)
AMZN   110.22 (+0.60%)
TSLA   663.10 (-2.74%)
NVDA   145.03 (-0.14%)
NIO   21.21 (-0.70%)
BABA   114.46 (-1.33%)
AMD   73.28 (-0.53%)
MU   54.43 (+1.45%)
CGC   2.66 (-5.34%)
T   20.83 (-2.25%)
GE   61.00 (-4.00%)
F   10.84 (-4.24%)
DIS   94.38 (-1.83%)
AMC   12.77 (-5.62%)
PFE   50.64 (-3.19%)
PYPL   71.76 (+0.50%)
NFLX   178.70 (-0.69%)
NASDAQ:LIVN

LivaNova Stock Forecast, Price & News

$61.97
-1.33 (-2.10%)
(As of 07/5/2022 11:25 AM ET)
Add
Compare
Today's Range
$60.93
$62.28
50-Day Range
$57.25
$80.19
52-Week Range
$56.13
$93.89
Volume
3,920 shs
Average Volume
329,384 shs
Market Capitalization
$3.31 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$101.50

LivaNova MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
60.3% Upside
$101.50 Price Target
Short Interest
Bearish
4.85% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.42mentions of LivaNova in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
25.00%
From $2.40 to $3.00 Per Share

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

2.19 out of 5 stars

Medical Sector

394th out of 1,428 stocks

Electromedical Equipment Industry

7th out of 30 stocks

30 days | 90 days | 365 days | Advanced Chart

Receive LIVN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for LivaNova and its competitors with MarketBeat's FREE daily newsletter.

LivaNova logo

About LivaNova (NASDAQ:LIVN) Stock

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates through three segments: Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products. The Neuromodulation segment designs, develops, and markets VNS Therapy System, an implantable device that delivers vagus nerve stimulation (VNS) therapy for the treatment of drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. It is also involved in the development and clinical testing of the VITARIA System for treating heart failure through VNS. The Advanced Circulatory Support segment develops, produces, and sells temporary life support products, such as cardiopulmonary and respiratory support solutions. The company serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. It sells its products through direct sales representatives and independent distributors. The company has a research collaboration with Verily to capture clinical biomarkers of depression. LivaNova PLC was founded in 1987 and is headquartered in London, the United Kingdom.

LIVN Stock News Headlines

LivaNova (NASDAQ:LIVN) Reaches New 52-Week Low at $57.10
Form DEFA14A LivaNova PLC - StreetInsider.com
See More Headlines

Industry, Sector and Symbol

Industry
Electromedical equipment
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:LIVN
Employees
3,000
Year Founded
N/A

Company Calendar

Last Earnings
5/04/2022
Today
7/05/2022
Next Earnings (Confirmed)
8/03/2022
Fiscal Year End
12/31/2022

Price Target and Rating

Average Stock Price Forecast
$101.50
High Stock Price Forecast
$108.00
Low Stock Price Forecast
$95.00
Forecasted Upside/Downside
+63.8%
Consensus Rating
Buy
Rating Score (0-4)
3
Research Coverage
6 Analysts

Profitability

Net Income
$-135,820,000.00
Pretax Margin
-8.84%

Debt

Sales & Book Value

Annual Sales
$1.04 billion
Cash Flow
$3.52 per share
Book Value
$24.32 per share

Miscellaneous

Free Float
53,243,000
Market Cap
$3.31 billion
Optionable
Optionable
Beta
0.92














LivaNova Frequently Asked Questions

Should I buy or sell LivaNova stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for LivaNova in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" LivaNova stock.
View analyst ratings for LivaNova
or view top-rated stocks.

What is LivaNova's stock price forecast for 2022?

6 Wall Street research analysts have issued 12 month price objectives for LivaNova's stock. Their LIVN stock forecasts range from $95.00 to $108.00. On average, they predict LivaNova's share price to reach $101.50 in the next twelve months. This suggests a possible upside of 63.8% from the stock's current price.
View analysts' price targets for LivaNova
or view top-rated stocks among Wall Street analysts.

How has LivaNova's stock price performed in 2022?

LivaNova's stock was trading at $87.43 at the beginning of the year. Since then, LIVN shares have decreased by 29.1% and is now trading at $61.97.
View the best growth stocks for 2022 here
.

When is LivaNova's next earnings date?

LivaNova is scheduled to release its next quarterly earnings announcement on Wednesday, August 3rd 2022.
View our earnings forecast for LivaNova
.

How can I listen to LivaNova's earnings call?

LivaNova will be holding an earnings conference call on Wednesday, August 3rd at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link.

How were LivaNova's earnings last quarter?

LivaNova PLC (NASDAQ:LIVN) released its quarterly earnings data on Wednesday, May, 4th. The company reported $0.48 EPS for the quarter, missing the consensus estimate of $0.52 by $0.04. The company earned $240.20 million during the quarter, compared to analyst estimates of $231.57 million. LivaNova had a negative net margin of 9.69% and a positive trailing twelve-month return on equity of 9.57%. The business's quarterly revenue was down 3.0% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.35 EPS.
View LivaNova's earnings history
.

What guidance has LivaNova issued on next quarter's earnings?

LivaNova updated its FY 2022 earnings guidance on Wednesday, May, 11th. The company provided earnings per share (EPS) guidance of $2.50-$2.80 for the period, compared to the consensus earnings per share estimate of $2.59. The company issued revenue guidance of $1.07 billion-$1.09 billion, compared to the consensus revenue estimate of $1.04 billion.

Who are LivaNova's key executives?

LivaNova's management team includes the following people:
  • Mr. Damien McDonald, CEO & Director (Age 57, Pay $3.48M)
  • Mr. Alex Shvartsburg, Chief Financial Officer (Age 51, Pay $888.04k)
  • Ms. Keyna Pidcock Skeffington, Sr. VP, Gen. Counsel & Corp. Sec. (Age 59, Pay $1.19M)
  • Ms. Trui Hebbelinck, Chief HR Officer (Age 50, Pay $945.32k)
  • Mr. Marco Dolci, Pres of Cardiopulmonary Bus. Unit (Age 60, Pay $1.29M) (LinkedIn Profile)
  • Deanna Wilke, Director of Corp. Communications
  • Mr. Matthew Joseph Dodds III, Sr. VP of Corp. Devel.
  • Dr. Bryan D. Olin Ph.D., Sr. VP & Head of Product Devel. - Neuromodulation (Age 55)
  • Mr. Paul R. Buckman, Pres of Advanced Circulatory Support & GM of Transcatheter Mitral Valve Replacement (Age 66)
  • Mr. Ryan Miller, Sr. VP of Strategy

What is Damien McDonald's approval rating as LivaNova's CEO?

47 employees have rated LivaNova CEO Damien McDonald on Glassdoor.com. Damien McDonald has an approval rating of 77% among LivaNova's employees.

What other stocks do shareholders of LivaNova own?

What is LivaNova's stock symbol?

LivaNova trades on the NASDAQ under the ticker symbol "LIVN."

How do I buy shares of LivaNova?

Shares of LIVN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is LivaNova's stock price today?

One share of LIVN stock can currently be purchased for approximately $61.97.

How much money does LivaNova make?

LivaNova (NASDAQ:LIVN) has a market capitalization of $3.31 billion and generates $1.04 billion in revenue each year. The company earns $-135,820,000.00 in net income (profit) each year or ($1.99) on an earnings per share basis.

How many employees does LivaNova have?

LivaNova employs 3,000 workers across the globe.

How can I contact LivaNova?

LivaNova's mailing address is 20 EASTBOURNE TERRACE, LONDON X0, W2 6LG. The official website for LivaNova is www.livanova.com. The company can be reached via phone at 442033250660, via email at investor.relations@livanova.com, or via fax at 281-218-9332.

This page (NASDAQ:LIVN) was last updated on 7/5/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.